Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 5/20 | 0.62 |
| ▸ | MAOA | P21397 | 4/20 | 0.58 |
| ▸ | MAOB | P27338 | 4/20 | 0.58 |
| ▸ | BCHE | P06276 | 1/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | HTR6 | P50406 | 1/20 | 0.58 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | FADS1 | O60427 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31046300 | 1.00 | HTR1A (0.62) | HTR1AMAOAMAOBBCHEADRA2B | |
| SCHEMBL1971780 | 1.00 | HTR1A (0.62) | HTR1AMAOAMAOBBCHEADRA2B | |
| Oxalic Acid SCHEMBL1974437 | 0.91 | HTR1A (0.54) | HTR1AMAOAMAOBBCHEADRA2B | |
| Oxalic Acid SCHEMBL1968009 | 0.91 | HTR1A (0.54) | HTR1AMAOAMAOBBCHEADRA2B | |
| SCHEMBL361398 | 0.90 | HTR1A (0.56) | HTR1AMAOAMAOBBCHEADRA2B | |
| Cadaverine Tartrate SCHEMBL6521196 | 0.87 | HTR1A (0.50) | HTR1AMAOAMAOBBCHEADRA2B | |
| Cadaverine Tartrate SCHEMBL1971585 | 0.87 | HTR1A (0.50) | HTR1AMAOAMAOBBCHEADRA2B | |
| SCHEMBL7538877 | 0.83 | SIGMAR1 (0.55) | HTR1AMAOAMAOBBCHEADRA2B | |
| SCHEMBL3890758 | 0.81 | MAOA (0.55) | HTR1AMAOAMAOBBCHEADRA2B | |
| SCHEMBL13618846 | 0.81 | MAOA (0.55) | HTR1AMAOAMAOBBCHEADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461388-B2 | Process for the synthesis of propargylated aminoindan derivatives | CIPLA LIMITED (IN) | 2013-06-11 | — | — | US | claimed |
| EP-2231582-B1 | PROCESS FOR THE SYNTHESIS OF PROPARGYLATED AMINOINDAN DERIVATIVES | CIPLA LTD (IN) | 2011-06-22 | — | — | EP | claimed |
| US-20110054218-A1 | Process for the Synthesis of Propargylated Aminoindan Derivatives | CIPLA LIMITED (IN) | 2011-03-03 | — | — | US | claimed |
| US-8461388-B2 | Process for the synthesis of propargylated aminoindan derivatives | CIPLA LIMITED (IN) | 2013-06-11 | — | — | US | disclosed |
| US-20110218360-A1 | PREPARATION OF RASAGILINE AND SALTS THEREOF | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-09-08 | — | — | US | disclosed |
| US-20110218360-A1 | PREPARATION OF RASAGILINE AND SALTS THEREOF | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-09-08 | — | — | US | disclosed |
| EP-2231582-B1 | PROCESS FOR THE SYNTHESIS OF PROPARGYLATED AMINOINDAN DERIVATIVES | CIPLA LTD (IN) | 2011-06-22 | — | — | EP | disclosed |
| US-20110054218-A1 | Process for the Synthesis of Propargylated Aminoindan Derivatives | CIPLA LIMITED (IN) | 2011-03-03 | — | — | US | disclosed |
| WO-2010059913-A2 | PREPARATION OF RASAGILINE AND SALTS THEREOF | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-05-27 | — | — | WO | disclosed |
| CN-1055468-C | New alkylaminoindane compounds, processes for preparing them and pharmaceutical compositions containing them | ADIR (FR) | 2000-08-16 | — | — | CN | disclosed |
| CN-1111620-A | New alkylaminoindane compounds, processes for preparing them and pharmaceutical compositions containing them | ADIR (FR) | 1995-11-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054218-A1 | Process for the Synthesis of Propargylated Aminoindan Derivatives | DAO, DDC, HRH2 | HTR1A 402/4885MAOA 811/4885MAOB 549/4885 |
| US-20110218360-A1 | PREPARATION OF RASAGILINE AND SALTS THEREOF | RAB35, RAB27A, RAB5C | HTR1A 503/4885MAOA 336/4885MAOB 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.